Clinical trials: Castration-Resistant Prostate Carcinoma, open to volunteers
Metastatic Castration-resistant Prostate Cancer
Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to Androgen Receptor (AR) and the other end to a ligand of E3 ligase (CRBN) via a linker.
- Trial name
- NCT07172126
- Testing
- TQB3201 tablets
- Where
- 3 sites in China
- Volunteers
- 291 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
- Trial name
- ProvONE (NCT06134232)
- Testing
- Sipuleucel-T Injection
- Where
- 31 sites in United States
- Volunteers
- 400 people
- Sponsor
- Dendreon
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.
- Trial name
- NCT06241846
- Testing
- YL201 for Injection
- Where
- 24 sites in China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer Patients
A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC
- Trial name
- NCT07135102
- Testing
- 225Ac-PSMA-XT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xiaorong Sun
Prostate Cancer Metastatic Castration-Resistant, Prostate Cancer
Liquid Biopsy Under PSMA Radioligand Therapy
Prostate cancer is the second most common cause of cancer death in men worldwide. After exhausting guideline-compliant therapies or in accordance with the approval of 177Lu-PSMA-617 (Pluvicto®), patients with metastatic…
- Trial name
- LOOPS (NCT07118436)
- Where
- 3 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Wuerzburg University Hospital
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
- Trial name
- NCT07104617
- Testing
- TY-302, Abiraptor
- Where
- China
- Volunteers
- 48 people
- Sponsor
- TYK Medicines, Inc
Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease
The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
In patients with metastatic prostate cancer (PCa) who receive androgen deprivation therapy (ADT), the sensitivity to castration will eventually disappear due to the selection of castration-refractory clones.
- Conditions
- Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease, Castration Resistant Metastatic Prostate Cancer, Radiotherapy
- Trial name
- OLYMPIAN (NCT07038304)
- Testing
- Metastasis directed radiotherapy
- Where
- 2 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- University Medical Center Groningen
Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a…
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis, Prostate Cancer (CRPC), Prostate Cancer
- Trial name
- NCT06972628
- Testing
- Administering Lutetium-177-PSMA-617 (PLUVICTO)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ebrahim S Delpassand
Metastatic Castration-resistant Prostate Cancer
Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC
This study is an open label, single arm, multicenter clinical trial. The aim of this study is to evaluate the efficacy, safety, and quality of life of radiotherapy combined with Fuzuloparib and Abiraterone Acetate Tablets（Ⅱ） as…
- Trial name
- PARTOM (NCT06971211)
- Testing
- Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jianbin Bi
Metastatic Castration-resistant Prostate Cancer
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
This is an open-label phase I/II study evaluating the addition of ebastine to docetaxel in the treatment for metastatic castration resistant prostate cancer.
- Trial name
- NCT06480110
- Testing
- Docetaxel + Ebastine, Docetaxel
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
ProBio is an international, outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven platform trial in patients with metastatic prostate cancer.
- Trial name
- ProBio (NCT03903835)
- Testing
- Enzalutamide Oral Capsule, Abiraterone Oral Tablet, Carboplatin
- Where
- 32 sites in Belgium, Norway and 2 more
- Volunteers
- 750 people
- Sponsor
- Karolinska Institutet
Metastatic Castration-resistant Prostate Cancer, MCRPC
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
A total of 75 participants will be enrolled in the study, with 25 participants allocated per intervention group. In Group 1, participant will take 50 mg cabazitaxel every week for 6 cycles (3 doses per cycle), 10 mg prednisone…
- Trial name
- NCT06890832
- Testing
- 50 mg cabazitaxel, 100 mg cabazitaxel, 200 mg cabazitaxel
- Volunteers
- 75 people
- Sponsor
- Jina Pharmaceuticals Inc.
Metastatic Castration Resistant Prostate Cancer
Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The goal of this clinical trial is to test GT-220F in patients with metastatic castration resistant prostate cancer and learn about the best dose required for further study.
- Trial name
- NCT06866795
- Testing
- GT-220F capsule
- Volunteers
- 42 people
- Sponsor
- Geode Therapeutics Inc.
Metastatic Prostate Adenocarcinoma, PSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
KuPSMALu-trial is an observational study for patients treated with 177LuPSMA-I\&T in Kuopio University Hospital, Finland. Study focuses on efficacy, safety and biomarker research.
- Trial name
- KuPSMALu (NCT06850545)
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Kuopio University Hospital
Metastatic Castration-resistant Prostate Cancer, MCRPC, Cancer
Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer
161Tb-NYM032 is a radiopharmaceutical labeled with a PSMA ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.
- Trial name
- NCT06827080
- Testing
- 30 mCi NYMO32, 50 mCi NYMO32, 80 mCi NYMO32
- Volunteers
- 15 people
- Sponsor
- Zhengguo Chen
Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer)
Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC
Acetate abiraterone tablets (II) is a modified new drug launched in China, prepared using nanocrystal technology and supplemented with SNAC as an absorption enhancer, working together to promote the gastrointestinal absorption of…
- Trial name
- mCRPC (NCT06768255)
- Testing
- Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT, Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Ding-Wei Ye
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA…
- Conditions
- Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases
- Trial name
- NCT06706921
- Testing
- 18F-Fluciclovine PET/CT Scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Castration-resistant Prostate Cancer, Oligoprogressive
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.
- Trial name
- MEDCARE (NCT06585007)
- Testing
- Radiotherapy, metastasectomy
- Where
- Belgium
- Volunteers
- 246 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Castration-resistant Prostate Cancer
Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study
Researchers will test a new treatment for prostate cancer. This treatment uses an antibody tagged with a small amount of radioactive material. Researchers believe the new antibody might work better than those used before.
- Trial name
- PROGNOSTICS (NCT06343038)
- Testing
- Injection, 161Tb-SibuDAB,1GBq, Injection, 177Lu-PSMA-I&T, 1GBq, Injection, 161Tb-SibuDAB, Dose Escalation
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- University Hospital, Basel, Switzerland